Klistorner, Alexander
Chai, Yi
Leocani, Letizia
Albrecht, Philipp
Aktas, Orhan
Butzkueven, Helmut
Ziemssen, Tjalf
Ziemssen, Focke
Frederiksen, Jette
Xu, Lei
Cadavid, Diego
Butzkueven, Helmut
Garrick, Ray
Vanopdenbosch, Ludo
Frederiksen, Jette
Aktas, Orhan
Albrecht, Philipp
Ziemssen, Focke
Ziemssen, Tjalf
Comi, Giancarlo
Dalmau, Bernardo Sánchez
Andersson, Magnus
Plant, Gordon T.
Matthews, Tim
Williams, Graeme
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
https://doi.org/10.1007/s40263-018-0575-8
Visual outcome measures in clinical trials of remyelinating drugs
https://doi.org/10.1136/bmjno-2023-000560
Funding for this research was provided by:
Biogen
Article History
First Online: 28 September 2018
Compliance with Ethical Standards
:
: This study was supported by Biogen (Cambridge, MA, USA). Biogen also provided funding for medical writing support in the development of this paper and for the open access fee.
: Alexander Klistorner has nothing to disclose. Yi Chai was a full-time employee of Biogen during the performance of the clinical trial, data analysis, and initial drafting of the manuscript. Letizia Leocani has received honoraria for consulting and/or speaking activities from Biogen, Merck, Roche, and Teva; research support from Biogen, Merck, and Novartis; and travel support from Almirall, Biogen, Merck, Novartis, and Roche. Philipp Albrecht has received grants from Biogen, the Dr. Robert Pfleger Foundation, Ipsen, Merz, and Novartis; received non-financial support from Bayer HealthCare, Ipsen, Merck, Merz, Novartis, Roche, and Teva; participated in advisory boards for Allergan, Ipsen, and Merz; and received personal fees from Allergan, Bayer HealthCare, Biogen, Ipsen, Novartis, Roche, and Teva, outside of the submitted work. Orhan Aktas has received advisor fees or honoraria from Almirall, Bayer HealthCare, Biogen, MedImmune, Merck, Novartis, and Teva; and research support from Bayer HealthCare, Biogen, Novartis, Roche, and Teva. Helmut Butzkueven has participated in advisory boards for Biogen, Merck, Novartis, and Teva; received consulting fees from Novartis and Oxford Pharmagenesis; lecture fees from Biogen; received payment for development of educational presentations from Biogen, Merck, and Novartis; and research grants from Biogen and Novartis, outside of the submitted work. Tjalf Ziemssen has received consulting fees from Almirall, Bayer HealthCare, Biogen, Genzyme, GlaxoSmithKline, Merck Serono, MSD, Novartis, Sanofi-Aventis, Synthon, and Teva; and research support from Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi-Aventis, and Teva. Focke Ziemssen has received consulting fees from Alimera, Allergan, Bayer HealthCare, Boehringer Ingelheim, Novartis, and Roche; and research support from Novartis. Jette Frederiksen has participated in scientific advisory boards for Almirall, Biogen, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, and Teva; received speaker honoraria from Biogen, Merck Serono, Santhera, and Teva; and been an advisor on preclinical development for Takeda, outside of the submitted work. Lei Xu was a full-time employee of Biogen during the performance of the clinical trial, data analysis, and initial drafting of the manuscript. Diego Cadavid was a full-time employee of Biogen during the performance of the clinical trial and a full-time employee of Fulcrum Therapeutics during submission of the manuscript; the work is not related to his employment in Fulcrum Therapeutics. He has patent WO 2016112270 A1: Lingo-1 antagonists and uses for treatment of demyelinating disorders, which is assigned to Biogen.
: All investigators obtained approval from their local ethics committees.
: All participants provided written informed consent and the study was performed in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki.